...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Schizophrenia research >Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
【24h】

Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms

机译：精神分裂症或精神分裂症和主要或显着阴性症状的患者对抗精神病药物治疗的反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with schizophrenia who have predominant negative symptoms are often considered less responsive to treatment. This analysis of patients with schizophrenia or schizoaffective disorder compares changes in symptom severity between those with predominant versus merely prominent negative symptoms. Prominent negative symptoms were defined by a baseline score of ≥ 4 on at least 3, or ≥ 5 on at least 2, of the 7 Positive and Negative Syndrome Scale (PANSS) negative subscale items. Predominant negative symptoms were defined by the foregoing plus a PANSS positive score of < 19, a Barnes Akathisia score of < 2, a Simpson-Angus score of < 4, and a Calgary Depressive Scale score of < 9. Adult patients with schizophrenia (n = 227) or schizoaffective disorder (n = 116) received either olanzapine (10-20. mg/day, n = 169) or quetiapine (300-700. mg/day, n = 174) for up to 24. weeks. Data for both medications were pooled. Of the 343 patients enrolled in the study, 34.7% met the criteria for predominant negative symptoms, the remaining 65.3% being characterized only by their prominent negative symptoms. Changes in the severity of negative symptoms in both patient types largely followed similar trajectories during treatment, as reflected both in Marder PANSS negative subscale scores and in the Scale for Assessment of Negative Symptoms total and domain scores. Patients with either predominant or prominent negative symptoms therefore appear to respond similarly to atypical antipsychotic treatment. This distinction, incorporating an evaluation of the presence of positive, affective, and extrapyramidal symptoms, may therefore not have prognostic implications for the responsiveness of patients' negative symptoms to treatment.
机译：精神分裂症患者主要表现为阴性症状，通常被认为对治疗反应较弱。这项对精神分裂症或精神分裂症患者的分析比较了主要症状和仅有明显阴性症状者之间症状严重程度的变化。显着的阴性症状是通过7个阳性和阴性综合征量表（PANSS）阴性子量表中至少3分的≥4或至少2分的≥5的基线得分定义的。主要的阴性症状由上述定义加上PANSS阳性评分<19，Barnes Akathisia评分<2，Simpson-Angus评分<4和卡尔加里抑郁量表评分<9。 = 227）或精神分裂性情感障碍（n = 116）接受奥氮平（10-20。mg /天，n = 169）或喹硫平（300-700。mg /天，n = 174）长达24周。合并两种药物的数据。在该研究的343名患者中，有34.7％符合主要阴性症状的标准，其余65.3％仅以其明显的阴性症状为特征。两种患者类型中阴性症状严重程度的变化在治疗过程中基本遵循相似的轨迹，这反映在Marder PANSS阴性子量表得分和阴性症状评估量表总分和领域分值中。因此，具有主要或显着阴性症状的患者似乎对非典型抗精神病药物的治疗反应相似。因此，这种区分包括对阳性，情感和锥体束外症状的评估，可能对患者阴性症状对治疗的反应性没有预后影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号